Cargando…
Clinical Advances in Molecular Biomarkers for Cancer Diagnosis and Therapy
Cancer diagnosis is currently undergoing a paradigm shift with the incorporation of molecular biomarkers as part of routine diagnostic panel. The molecular alteration ranges from those involving the DNA, RNA, microRNAs (miRNAs) and proteins. The miRNAs are recently discovered small non-coding endoge...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Molecular Diversity Preservation International (MDPI)
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3742272/ https://www.ncbi.nlm.nih.gov/pubmed/23863689 http://dx.doi.org/10.3390/ijms140714771 |
_version_ | 1782280348594339840 |
---|---|
author | Sethi, Seema Ali, Shadan Philip, Philip A. Sarkar, Fazlul H. |
author_facet | Sethi, Seema Ali, Shadan Philip, Philip A. Sarkar, Fazlul H. |
author_sort | Sethi, Seema |
collection | PubMed |
description | Cancer diagnosis is currently undergoing a paradigm shift with the incorporation of molecular biomarkers as part of routine diagnostic panel. The molecular alteration ranges from those involving the DNA, RNA, microRNAs (miRNAs) and proteins. The miRNAs are recently discovered small non-coding endogenous single-stranded RNAs that critically regulates the development, invasion and metastasis of cancers. They are altered in cancers and have the potential to serve as diagnostic markers for cancer. Moreover, deregulating their activity offers novel cancer therapeutic approaches. The availability of high throughput techniques for the identification of altered cellular molecules allowed their use in cancer diagnosis. Their application to a variety of body specimens from blood to tissues has been helpful for appreciating their use in the clinical context. The development of innovative antibodies for immunohistochemical detection of proteins also assists in diagnosis and risk stratification. Overall, the novel cancer diagnostic tools have extended their application as prognostic risk factors and can be used as targets for personalized medicine. |
format | Online Article Text |
id | pubmed-3742272 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Molecular Diversity Preservation International (MDPI) |
record_format | MEDLINE/PubMed |
spelling | pubmed-37422722013-08-13 Clinical Advances in Molecular Biomarkers for Cancer Diagnosis and Therapy Sethi, Seema Ali, Shadan Philip, Philip A. Sarkar, Fazlul H. Int J Mol Sci Review Cancer diagnosis is currently undergoing a paradigm shift with the incorporation of molecular biomarkers as part of routine diagnostic panel. The molecular alteration ranges from those involving the DNA, RNA, microRNAs (miRNAs) and proteins. The miRNAs are recently discovered small non-coding endogenous single-stranded RNAs that critically regulates the development, invasion and metastasis of cancers. They are altered in cancers and have the potential to serve as diagnostic markers for cancer. Moreover, deregulating their activity offers novel cancer therapeutic approaches. The availability of high throughput techniques for the identification of altered cellular molecules allowed their use in cancer diagnosis. Their application to a variety of body specimens from blood to tissues has been helpful for appreciating their use in the clinical context. The development of innovative antibodies for immunohistochemical detection of proteins also assists in diagnosis and risk stratification. Overall, the novel cancer diagnostic tools have extended their application as prognostic risk factors and can be used as targets for personalized medicine. Molecular Diversity Preservation International (MDPI) 2013-07-16 /pmc/articles/PMC3742272/ /pubmed/23863689 http://dx.doi.org/10.3390/ijms140714771 Text en © 2013 by the authors; licensee MDPI, Basel, Switzerland http://creativecommons.org/licenses/by/3.0 This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/). |
spellingShingle | Review Sethi, Seema Ali, Shadan Philip, Philip A. Sarkar, Fazlul H. Clinical Advances in Molecular Biomarkers for Cancer Diagnosis and Therapy |
title | Clinical Advances in Molecular Biomarkers for Cancer Diagnosis and Therapy |
title_full | Clinical Advances in Molecular Biomarkers for Cancer Diagnosis and Therapy |
title_fullStr | Clinical Advances in Molecular Biomarkers for Cancer Diagnosis and Therapy |
title_full_unstemmed | Clinical Advances in Molecular Biomarkers for Cancer Diagnosis and Therapy |
title_short | Clinical Advances in Molecular Biomarkers for Cancer Diagnosis and Therapy |
title_sort | clinical advances in molecular biomarkers for cancer diagnosis and therapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3742272/ https://www.ncbi.nlm.nih.gov/pubmed/23863689 http://dx.doi.org/10.3390/ijms140714771 |
work_keys_str_mv | AT sethiseema clinicaladvancesinmolecularbiomarkersforcancerdiagnosisandtherapy AT alishadan clinicaladvancesinmolecularbiomarkersforcancerdiagnosisandtherapy AT philipphilipa clinicaladvancesinmolecularbiomarkersforcancerdiagnosisandtherapy AT sarkarfazlulh clinicaladvancesinmolecularbiomarkersforcancerdiagnosisandtherapy |